MicroPhage plans further development of the test through 2009 and will enter it into FDA clinical trials in early 2010. The company plans to format the product like its blood culture test and provide antibiotic susceptibility and resistance results which aid in determining if the S. aureus present is methicillin-resistant (MRSA) or sensitive (MSSA), further directing appropriate therapy. The product is planned to reach the US market later next year.
